Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Rudy Christmas"'
Autor:
Manfred Kraus, Aniela Jakubowski, Yulia Rybakova, Nicole Lessard, Rudy Christmas, Tom Addison, Leona Lee, Jieni Xu, Mark Krimmer, Cafer Ozdemir, Burak Yilmaz, Yusuf Erkul, Isaak Mueller
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/837edb6eb795455aaff92eb599be86a3
Autor:
Daniel S. Leventhal, Anna Sokolovska, Ning Li, Christopher Plescia, Starsha A. Kolodziej, Carey W. Gallant, Rudy Christmas, Jian-Rong Gao, Michael J. James, Andres Abin-Fuentes, Munira Momin, Christopher Bergeron, Adam Fisher, Paul F. Miller, Kip A. West, Jose M. Lora
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Synthetic biology can be used to create rationally designed living therapeutics. Here the authors engineer E. coli Nissle to target STING activation in antigen presenting cells for the treatment of solid tumors and demonstrate preclinical activity in
Externí odkaz:
https://doaj.org/article/c274837c940442a5b5b9051d086275aa
Autor:
Manfred Kraus, Rudy Christmas, Tom A. Addison, Yulia Rybakova, Leona Lee, Jieni Xu, Mark Krimmer, Cafer Ozdemir, Burak Yilmaz, Yusuf Erkul
Publikováno v:
Cancer Research. 83:3232-3232
Novel improved cancer immunotherapies are needed, since most cancer patients exhibit a treatment resistant tumor microenvironment to currently available immunotherapeutic modalities. Due to primary resistance or the development of acquired resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ad865be37f34f7eb9ca264f4992b147
https://doi.org/10.1158/1538-7445.am2023-3232
https://doi.org/10.1158/1538-7445.am2023-3232
Autor:
Carey W. Gallant, Christopher Plescia, Paul F. Miller, Michael J. James, Kip A. West, Rudy Christmas, Daniel S. Leventhal, Jian-Rong Gao, Ning Li, Adam B. Fisher, Starsha Kolodziej, Munira Momin, Christopher Bergeron, Anna Sokolovska, Andres Abin-Fuentes, Jose M. Lora
Publikováno v:
Nature Communications
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Nature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
Synthetic biology is a powerful tool to create therapeutics which can be rationally designed to enable unique and combinatorial functionalities. Here we utilize non-pathogenic E coli Nissle as a versatile platform for the development of a living biot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76faebc0aaf2c966e92df019edccdf75
http://europepmc.org/articles/PMC7264239
http://europepmc.org/articles/PMC7264239
Autor:
Karuppiah Kannan, Rudy Christmas, Stephen Tirrell, Mengkun Zhang, Zhongmin Xiang, Jie Yu, Jessica J. Sappal, Matthew Theisen
Publikováno v:
Cancer Research. 78:3844-3844
TAK-659 is a highly potent, reversible inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3) that is currently being investigated in Phase I and II clinical trials. SYK is expressed ubiquitously in hematopoietic cells, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c1667df38f6f0342447a6a7156ee909
https://doi.org/10.1158/1538-7445.am2018-3844
https://doi.org/10.1158/1538-7445.am2018-3844